Prevention With a Purpose
People may benefit from having a variety of HIV prevention options that best fit into their life. HIV has affected certain populations disproportionally. Representation of those communities in HIV clinical trials is important. We are committed to help end the HIV epidemic. The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV—also known as pre-exposure prophylaxis (PrEP).
Inclusion is important—the PURPOSE clinical trials are reaching out to ensure that those who may benefit most from HIV prevention are represented. See below to find out if you qualify for one of the lenacapavir trials.
For more information on lenacapavir in clinical trials, please click here.
PrEP Studies Overview
About PURPOSE 1
- Phase 3 study of an investigational drug, lenacapavir, for PrEP and emtricitabine/tenofovir alafenamide (F/TAF) for PrEP in Adolescent Girls and Young Women
- This study will be conducted in South Africa and Uganda
About PURPOSE 2
- Phase 3 study of an investigational drug, lenacapavir, for PrEP for Cisgender Men, Transgender Women, Transgender Men, and Gender Non-Binary individuals Who Have Sex With Partners Assigned Male at Birth
- This study will be conducted in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand
PURPOSE study investigators, please click here.
PrEP Studies Overview
About PURPOSE 3
- Phase 2 study of an investigational drug, lenacapavir, for PrEP in Cisgender Adult Women
- This study will be conducted in the United States
About PURPOSE 4
- Phase 3 study of an investigational drug, lenacapavir, for PrEP among people who inject drugs
- This study will be conducted in the United States
PURPOSE study investigators, please click here.
Looking Forward
We have come a long way in the fight against HIV. The development of drugs to prevent and treat HIV has changed the course of the epidemic. But our work is not done.
Lenacapavir Is an Investigational Product
Its safety and efficacy have not been established and it has not been approved for HIV prevention by any regulatory authority. The safety and efficacy of F/TAF for PrEP in cisgender women has not been established and it is not approved for reducing the chance of getting HIV through vaginal sex.
Curious About PURPOSE 1?
PURPOSE 1, which will enroll cisgender women, will evaluate an investigational drug, lenacapavir, and an FDA-approved PrEP drug, emtricitabine/tenofovir alafenamide, also known as F/TAF or DESCOVY®, for PrEP. This trial is taking place in South Africa and Uganda and has completed enrollment.
Learn more about PURPOSE 1Want to Know More About PURPOSE 2?
PURPOSE 2 will evaluate an investigational drug, lenacapavir, and will enroll cisgender men, transgender women, transgender men, and gender non-binary individuals who have sex with partners assigned male at birth. This trial is taking place in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand.
Learn more about PURPOSE 2Is PURPOSE 3 for You?
PURPOSE 3 will evaluate an investigational drug, lenacapavir, and will enroll cisgender adult women. This trial is taking place in the United States.
Learn more about PURPOSE 3Want to Learn More About PURPOSE 4?
PURPOSE 4 will evaluate an investigational drug, lenacapavir, and will enroll adults who inject drugs. This trial is taking place in the United States.
Learn more about PURPOSE 4Our Goal? Community Inclusion.
Meet Our Community Advisors
The commitment Gilead has to inclusion is reflected in the widely diverse and accomplished individuals who have served as community advisors. Learn more about the people who contributed to the shaping of the PURPOSE study protocols.
PURPOSE 1: Yvette Raphael
PURPOSE 2: Jenna Rapues
PURPOSE 1: Yvette Raphael
PURPOSE 2: Jenna Rapues
